Further, cell cycle regulators, such as LEM4, have been found to render ER + breast cancer cells resistant to tamoxifen when overexpressed through ERα signaling and activation of the cyclin D-CDK4/6 axis (184). This evidence concerns the gene ESR1 and breast carcinoma.